课题基金 / 基金详情

Structural Characterization of APOBECS's Atomic interactions

Structural Characterization of APOBECS's Atomic interactions
APOBECS 原子相互作用的结构表征
批准号：
8078336
负责人：
Celia A. Schiffer
金额：
$35.01万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
项目状态：
已结题
起止时间：
2011-03-01 至 2015-12-31
来源：
https://reporter.nih.gov/project-details/8078336
关键词：
APRIN geneActive SitesBindingBinding SitesBiochemicalBiochemistryBiological AssayCalorimetryCatalytic DomainChargeCollaborationsComplexCore ProteinCrystallizationCytidine DeaminaseCytosine deaminaseDNADataDiseaseDockingEnzymesEquilibriumFamilyGoalsGrantGuidelinesHIVHIV therapyHIV-1HomoHomology ModelingHuman bodyImageryInfectionInvestigationLigandsMapsMass Spectrum AnalysisModelingMolecularMolecular ModelsMutateMutationPathway interactionsPeptidesPharmaceutical PreparationsPharmacotherapyProtein FamilyProteinsResolutionRoleSeriesShapesSolutionsSpecificityStructureSubstrate InteractionSurfaceTechniquesTestingVariantViralViral PhysiologyVirusVirus DiseasesWorkZincacrosome stabilizing factoranalogcrosslinkdesigninhibitor/antagonistinterdisciplinary approachmacromoleculemolecular modelingmutantnovelpreventresponsescaffoldsmall moleculevirology

项目摘要

项目成果

Celia A. Schiffer的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The APOBECS's (A3G, ASF and possibly A3H) are cellular DNA cytosine deaminases that are key innate anti-viral agents, particularly in response to HIV-1. Although the structures of the catalytic domains of these important enzymes are beginning to be elucidated, the details of their specificities and interactions with other cellular and viral macromolecules still remains to be determined. In this proposal we are using a combination of crystallographic, molecular modelling, calorimetry, mass spectrometry and viral studies to characterize the domains of these various APOBEC3's, both intra-moleculariy within their domains and intermoleculariy with their interactions with HIV-1 Vif.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Integration of Evolution to Avoid Resistance in Structure Based Drug Design
Integration of Evolution to Avoid Resistance in Structure Based Drug Design
Design of Protease Inhibitors to Target HTLV-1
Integration of Evolution to Avoid Resistance in Structure Based Drug Design
海外基金